31-Jul-2026
Insmed to Host Second-Quarter 2026 Financial Results Conference Call on Thursday, August 6, 2026
PRNewswire (Thu, 23-Jul 7:39 AM ET)
Market Chameleon (Thu, 16-Jul 4:33 AM ET)
PRNewswire (Thu, 16-Jul 7:00 AM ET)
Globe Newswire (Tue, 30-Jun 7:30 AM ET)
Insmed Appoints Samuele Butera as Senior Vice President, General Manager, Global Respiratory
PRNewswire (Tue, 23-Jun 7:01 AM ET)
Nasdaq-100 Index June 2026 Quarterly Changes
Globe Newswire (Thu, 11-Jun 8:00 PM ET)
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PRNewswire (Thu, 4-Jun 7:00 AM ET)
Insmed to Spotlight Innovation at 2026 Goldman Sachs Annual Global Healthcare Conference
Market Chameleon (Wed, 27-May 3:52 AM ET)
Insmed to Present at the 2026 Goldman Sachs Annual Global Healthcare Conference
PRNewswire (Wed, 27-May 7:00 AM ET)
Insmed Delivers Strong First-Quarter Revenue Growth as BRINSUPRI Momentum Accelerates
Market Chameleon (Thu, 7-May 3:45 AM ET)
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
Insmed trades on the NASDAQ stock market under the symbol INSM.
As of July 31, 2026, INSM stock price declined to $98.60 with 2,649,393 million shares trading.
INSM has a beta of 0.22, meaning it tends to be less sensitive to market movements. INSM has a correlation of 0.00 to the broad based SPY ETF.
INSM has a market cap of $21.37 billion. This is considered a Large Cap stock.
Last quarter Insmed reported $306 million in Revenue and -$.76 earnings per share. This beat revenue expectation by $4 million and exceeded earnings estimates by $.22.
In the last 3 years, INSM traded as high as $212.75 and as low as $20.94.
The top ETF exchange traded funds that INSM belongs to (by Net Assets): VTI, VXF, VB, VO, VUG.
INSM has underperformed the market in the last year with a price return of -8.1% while the SPY ETF gained +19.4%. INSM has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -27.7% and -9.0%, respectively, while the SPY returned +4.2% and +0.5%, respectively.
INSM support price is $99.00 and resistance is $103.98 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INSM shares will trade within this expected range on the day.